Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective

This Danish study aimed to assess the impact of age and comorbidities on PFS and OS for patients with ER-positive, HER2 normal, advanced breast cancer treated with palbociclib and AI. In this MEDtalk, Alan Celik, MD, Danish Breast Cancer Group (DBCG), presents the results from the study.